What is PHVS's current stock price?

PHVS (Pharvaris N.V.) is currently trading at $29.68 with a market cap of $1.94B.

What sector is Pharvaris N.V. in?

Pharvaris N.V. (PHVS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PHVS a good stock to buy?

Analysts have a Buy consensus on PHVS with a price target of $48.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PHVS Pharvaris N.V.

Healthcare

$29.68-2.82%ClosedMarket Cap: $1.94B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

7.04

P/S

0.00

EV/EBITDA

-8.37

DCF Value

$5.70

FCF Yield

-8.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-67.4%

ROA

-65.1%

ROIC

-72.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-39.8M	$—
Q4 null	$0.00	$-46.7M	$—
FY null	$0.00	$-175.7M	$—
Q3 null	$0.00	$-37.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$48.00

Target (Median)

$42.00

Target Range

$38.00 - $74.00

3 Strong Buy9 Buy1 Hold0 Sell0 Strong Sell

CitizensMarket Outperform

2026-05-13

WedbushOutperform

2026-04-07

RBC CapitalOutperform

2026-04-06

HC Wainwright & Co.Buy

2026-03-03

GuggenheimBuy

2025-12-04

Trading Activity

Insider Trades

View All

Modig Berndt

SellFri May 22

Bjork Elisabethdirector

SellFri May 22

Bjork Elisabethdirector

SellFri May 22

Modig Berndtdirector, officer: Chief Executive Officer

SellWed May 20

Souverijns Wimofficer: Chief Commercial Officer

SellTue May 19

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-2.33

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Peers

UPB